

Comprehensive Health Insights.



Diving into data

Humana's data powered by PearlDiver's research software, creating customizable, longitudinal and publishable research for your needs

Comprehensive Health Insights partners with PearlDiver, to offer a new data mining tool for faster, more comprehensive research

This service capitalizes on Humana's rich claims database containing diagnoses, procedures, pharmacological records and lab test results, combined with PearlDiver's fast and customizable research capabilities. All data is fully HIPAA-compliant and works with PearlDiver's proprietary longitudinal mining software, allowing for Web access to perform research across private payer and Medicare populations. Benefits of this joint venture include:

- Customizable and fast research
- Unlimited number of queries allowed in your annual subscription
- Ability to refine research hypotheses as research progresses
- Longitudinal tracking of customized patient groups
- Ability to create custom cohorts of patients based upon diagnoses and/or procedures
- Publishable results

Researchable data

- Diagnosis volumes
- Reimbursement
- Lab results
- Procedure volumes
- Prescription use

Common answerable business questions

- What is the total cost of care for the diagnosed disease state and what contributes to it?
- What are the readmission rates for the diagnosed disease state?
- What are the patterns of care for this disease state?



"Studies that were once performed over months and years now can be done over an entire population in minutes."

Bejamin Young,
President, PearlDiver

"This functionality provides the ability to answer real world research questions in real time."

Steve Chick,
Vice President CHI



Humana.com



Unmatched service

One year unlimited web access with training and support included.

PearlDiver referenced research

- **Werner BC, Brockmeier SF, Gwathmey FW.** “Trends in Long Head Biceps Tenodesis.” American Journal of Sports Medicine, 2014 Dec.
- **McCormick R, Harris JD, et al.** “Trends in the surgical treatment of articular cartilage lesions in the United States: an analysis of a large private-payer database over a period of 8 years.” Arthroscopy. 2014 Feb;30(2):22-6.
- **Nwachukwu BU, McCormick F, Provencher MT, Roche M, Rubash HE.** “A Comprehensive Analysis of Medicare Trends in Utilization and Hospital Economics for Total Knee and Hip Arthroplasty From 2005 to 2011.” Journal of Arthroplasty, 2014 Sep 6. pii: S0883-5403(14)00614-7.
- **Dhawan A, Mather RC, et al.** “An epidemiologic analysis of clinical practice guidelines for non-arthroplasty treatment of osteoarthritis of the knee.” Arthroscopy. 2014 Jan;30(1):65-71..
- **Montgomery SR, Zhang A, et al.** Cross-sectional analysis of trends in meniscectomy and meniscus repair. Orthopedics. 2013 Aug;36(8):e1007-13.
- **Terrell RD, Montgomery SR, et al.** “Comparison of practice patterns in total ankle replacement and ankle fusion in the United States.” Foot & Ankle International. 2013 Nov;34(11):1486-92.
- **Montgomery SR, Ngo SS, et al.** “Trends and demographics in hip arthroscopy in the United States.” Arthroscopy. 2013 Apr;29(4):661-5.
- **Zusman NL, Ching AC, et al.** “Incidence of second cervical vertebral fractures far surpassed the rate predicted by the changing age distribution and growth among elderly persons in the United States (2005-2008).” Spine. 2013 Apr 20;38(9):752-6.
- **Pal S, Besier TF, Draper CE, Fredericson M, Gold GE, Beaupre GS, Delp SL.** “Patellar tilt correlates with vastus lateralis: vastus medialis activation ratio in maltracking patellofemoral pain patients.” Journal of Orthopaedic Research. 2012 Jun;30(6):927-33.
- **Kelly M, Savage J, Bentzen S, Hsu WK, Ellison S, Anderson P.** “Cancer Risk From Bone Morphogenetic Protein Exposure In Spinal Arthrodesis.” Journal Of Bone Joint Surgery, 2014 Sep 03;96(17):1417--1422.

Your business has questions and we have the answers

- What are the demographics of the patients meeting identifying criteria?
- What comorbidities exist for the diagnosed disease state?
- What are the readmission rates for the diagnosed disease state?
- What is the probability of survival for this group of patients?
- What are the patterns of care for this disease state?
- How many patients were misdiagnosed or underdiagnosed?
- What are the treatment trends for the identified disease state?



For more information:

- Contact Jeff France: jfrance1@humana.com or (480)600-3562
- Contact Scott Ellison: scott@pearldiverinc.com or (260)468-3636

Humana®

Humana.com

